Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rilzabrutinib trial for prevention of vaso-occlusive crises in sickle-cell disease
NL-OMON59610Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Annualized rate of clinical vaso-occlusive crisis. Planned start May 2025; status: not yet recruiting.
02
Drugs
rilzabrutinib
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON59610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59610.